ABL Bio Inc Cash Flow-to-Debt Ratio
ABL Bio Inc cash flow-to-debt ratio. ABL Bio Inc (298380) has a Cash Flow-to-Debt Ratio of -0.23x as of June 2026, meaning its operating cash flow of ₩-23.42 Billion could theoretically repay 0% of its total liabilities (₩99.78 Billion) in one year. Check ABL Bio Inc cash flow quality index to evaluate the quality of earnings relative to operating cash generation.
CF-to-Debt Ratio
Operating Cash Flow
Total Liabilities
Data as of
Cash Flow-to-Debt Ratio of ABL Bio Inc (2016–2025)
Cash flow-to-debt ratio of ABL Bio Inc from 2016 to 2025. Historical debt coverage capacity for ABL Bio Inc across 10 annual periods. Check ABL Bio Inc (298380) total reinvestment rate to assess the company's total reinvestment commitment from operating cash flow.
ABL Bio Inc Cash Flow-to-Debt Ratio by Year (2016–2025)
ABL Bio Inc cash flow-to-debt ratio by year from 2016 to 2025. Year-by-year debt coverage analysis for ABL Bio Inc. For the full cash flow conversion analysis, see 298380 operating cash flow.
| Year | CF-to-Debt Ratio | Operating CF (KRW) | Total Liabilities | YoY Change |
|---|---|---|---|---|
| 2025 | -0.33x | ₩-41.25 Billion | ₩124.24 Billion | ▲ +69.0% |
| 2024 | -1.07x | ₩-69.40 Billion | ₩64.70 Billion | ▼ -225.5% |
| 2023 | -0.33x | ₩-28.36 Billion | ₩86.07 Billion | ▼ -152.8% |
| 2022 | 0.62x | ₩72.13 Billion | ₩115.67 Billion | ▲ +114.6% |
| 2021 | -4.27x | ₩-40.61 Billion | ₩9.50 Billion | ▲ +16.6% |
| 2020 | -5.12x | ₩-47.29 Billion | ₩9.23 Billion | ▼ -134.0% |
| 2019 | -2.19x | ₩-23.86 Billion | ₩10.89 Billion | ▼ -105.8% |
| 2018 | -1.06x | ₩-12.67 Billion | ₩11.91 Billion | ▼ -1483.8% |
| 2017 | -0.07x | ₩-7.14 Billion | ₩106.32 Billion | ▲ +57.7% |
| 2016 | -0.16x | ₩-3.12 Billion | ₩19.63 Billion | — |